NCT02836483View on ClinicalTrials.gov

A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

December 10, 2016

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

LCB01-0371 800mg, QD

Oral administration

DRUG

LCB01-0371 400mg, BID

Oral administration

DRUG

LCB01-0371 800mg, BID

Oral administration

DRUG

Tubes 3~5Tablet, QD

Oral administration

DRUG

Zyvox 600mg, BID

Oral administration

DRUG

LCB01-0371 1200mg, QD

Oral administration

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

LigaChem Biosciences, Inc.

INDUSTRY

NCT02836483 - A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK | Biotech Hunter | Biotech Hunter